<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Immunometabolic Gatekeeping: Reconciling Peto's & the T-cell Infiltration Prognostic Paradox - Health AI Hub</title>
    <meta name="description" content="This paper introduces the 'immunometabolic gatekeeping' framework, proposing that a tissue's intrinsic metabolic intensity and waste-handling capacity are upstr">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Immunometabolic Gatekeeping: Reconciling Peto's & the T-cell Infiltration Prognostic Paradox</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.20883v1" target="_blank">2511.20883v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-25
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Naomi Iris van den Berg, Matou≈° Elphick, Kevin Mulder, Omar Bouricha, Omid Sadeghi-Alavijeh, Xiao Fu, Samra Turajlic
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> q-bio.TO
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.90 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.20883v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.20883v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces the 'immunometabolic gatekeeping' framework, proposing that a tissue's intrinsic metabolic intensity and waste-handling capacity are upstream determinants of anti-tumour immunity, influencing whether immune infiltration translates into effective function. It reconciles several paradoxes, including Peto's paradox and the T-cell infiltration prognostic paradox, by positing that high-metabolism tissues with poor waste clearance create immune-exhausting niches even before malignant transformation. This framework shifts focus from tumor-intrinsic mutations to host tissue metabolism as a critical factor in cancer vulnerability and immune failure.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research offers a novel, integrative lens on cancer vulnerability by highlighting the critical, often overlooked, role of host tissue metabolism in shaping immune responses to cancer. It provides a foundational shift that could lead to new biomarkers for risk assessment and the development of metabolic-immune targeted therapies for prevention and treatment across various cancers.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The abstract does not explicitly mention the use of AI or propose specific AI applications. While 'integrative synthesis spanning human single-cell expression data' might in future research leverage AI/machine learning for pattern recognition or biomarker discovery, the current abstract does not describe such an application.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>**Immunometabolic Gatekeeping Framework:** Proposes that tissue-intrinsic metabolic intensity and waste-handling capacity act as an upstream gatekeeper for anti-tumour immunity, determining immune efficacy.</li>
                    
                    <li>**Reconciliation of Paradoxes:** The framework unifies explanations for Peto's paradox (cancer incidence vs. body size), T-cell infiltration non-prognosticity, tissue tropisms, and sex-based inequalities in cancer vulnerability.</li>
                    
                    <li>**Human Cancer Observations:** Tumors arising in high-metabolism tissues (e.g., kidney, brain, eye) exhibit high T-cell infiltration but are associated with poor prognosis, suggesting pre-existing metabolic environments undermine immune function.</li>
                    
                    <li>**Cross-Species Validation:** Large mammals with lower mass-specific metabolic rates accumulate fewer metabolic byproducts and show lower cancer incidence (Peto's paradox). Similarly, long-lived small mammals like bats and naked mole-rats resist tumorigenesis via suppressed glycolysis or altered hypoxia responses, leading to lower metabolic rates/byproduct accumulation.</li>
                    
                    <li>**Pre-Existing Immune Exhaustion:** The core hypothesis is that high metabolic rates and poor waste clearance in tissues foster immune-exhausting niches even prior to malignant transformation.</li>
                    
                    <li>**Methodological Approach:** The framework is developed through an integrative synthesis of evidence, including human single-cell expression data and cross-species comparisons.</li>
                    
                    <li>**Clinical Implications:** Suggests new principles for identifying high-risk patients and developing metabolic-immune combination strategies for both cancer prevention and treatment.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The study employs an 'integrative synthesis' approach, combining analyses of human single-cell expression data with cross-species comparative analyses to build and support the 'immunometabolic gatekeeping' framework.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The intrinsic metabolic intensity and waste-handling capacity of healthy tissues function as an 'immunometabolic gatekeeper,' critically determining the efficacy of anti-tumour immunity. High-metabolism tissues in humans show high T-cell infiltration but poor cancer prognosis, paralleled by cross-species observations (Peto's paradox). This indicates that metabolically intense environments with poor waste clearance create immune-exhausting niches even before malignancy, unifying several long-standing paradoxes in cancer biology.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This framework could lead to the development of novel tools for identifying individuals at high risk of cancer based on their tissue metabolic profiles. It also paves the way for new metabolic-immune combination strategies for cancer prevention and treatment, moving beyond tumor-centric therapies to target the host tissue environment. This offers a potential paradigm shift in personalized medicine for cancer.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract, while proposing a comprehensive framework based on integrative synthesis, does not explicitly detail direct experimental validation of the proposed 'immunometabolic gatekeeping' mechanism or its clinical application in intervention trials. Further mechanistic studies and clinical validation are implied as necessary next steps.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>Future research should focus on developing methods for identifying high-risk patients based on tissue-specific metabolic profiles. It also points towards the design and testing of metabolic-immune combination strategies for cancer prevention and treatment, potentially involving pharmacological or lifestyle interventions aimed at modulating host tissue metabolism and waste clearance.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Immunology</span>
                    
                    <span class="tag">Metabolism</span>
                    
                    <span class="tag">Cancer Prevention</span>
                    
                    <span class="tag">Personalized Medicine</span>
                    
                    <span class="tag">Geriatric Oncology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Immunometabolism</span>
                    
                    <span class="tag tag-keyword">Peto's Paradox</span>
                    
                    <span class="tag tag-keyword">T-cell infiltration</span>
                    
                    <span class="tag tag-keyword">Cancer prognosis</span>
                    
                    <span class="tag tag-keyword">Tissue metabolism</span>
                    
                    <span class="tag tag-keyword">Immune exhaustion</span>
                    
                    <span class="tag tag-keyword">Host-tumor interaction</span>
                    
                    <span class="tag tag-keyword">Cancer prevention</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Classical models of cancer focus on tumour-intrinsic genetic aberrations and immune dynamics and often overlook how the metabolic environment of healthy tissues shapes tumour development and immune efficacy. Here, we propose that tissue-intrinsic metabolic intensity and waste-handling capacity act as an upstream gatekeeper of anti-tumour immunity, determining whether immune infiltration translates into effective immune function and safeguards the tissue from tumourigenesis. Across human cancers, tumours arising in high-metabolism tissues - like kidney, brain, and eye - tend to show high T cell infiltration but poor prognosis, suggesting pre-existing metabolic environments prior to malignant transformation may undermine immune function. This pattern is mirrored across species: large mammals with lower mass-specific metabolic rates (e.g., elephants, whales) accumulate fewer metabolic byproducts and show lower cancer incidence (Peto's paradox), while long-lived small mammals like bats and naked mole-rats resist tumourigenesis via suppressed glycolysis or altered hypoxia responses leading to lower metabolic rates and/or byproduct accumulation. Through integrative synthesis spanning human single-cell expression data and cross-species comparisons, we outline a framework of 'immunometabolic gatekeeping', where tissues with high metabolic rate and poor waste clearance foster immune-exhausting niches even before transformation. This unifying framework reconciles multiple paradoxes in cancer biology: Peto's paradox, T cell infiltration non-prognosticity, tissue tropisms, and sex-based inequalities, and suggests new principles for identifying high-risk patients and metabolic-immune combination strategies for prevention and treatment. By shifting focus from tumour-intrinsic mutations to host-tissue metabolism, this work offers a novel, integrative lens on cancer vulnerability and immune failure.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>31 pages (including Supplementary materials), 4 main figures</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>